Blood test could spare some kidney cancer patients from unnecessary drugs
NCT ID NCT06005818
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is for people with high-risk kidney cancer that has been surgically removed. It uses a blood test to look for tiny bits of cancer DNA (molecular residual disease). If no DNA is found, patients skip standard immunotherapy (pembrolizumab); if DNA is found, they receive it. The goal is to see if this personalized approach improves how long patients stay cancer-free and overall survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Pembrolizumab (a drug that helps the immune system fight cancer)
- What this could lead to
- If successful, this could show that using a blood test to detect leftover cancer DNA helps decide who needs further treatment, potentially sparing some patients from unnecessary therapy.
- What could go wrong
- This is a small, early-phase (Phase 2) trial with only 100 participants. The approach may not improve survival or could miss some cancers. Pembrolizumab can cause immune-related side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLEAR CELL RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Alabama at Birmingham
RECRUITINGBirmingham, Alabama, 35233, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can we predict who needs extra therapy after kidney cancer surgery?
- Can a Two-Pronged immune attack shrink kidney tumors before surgery?
- Can a Two-Drug combo outsmart advanced cancers?
- Can a rapid drug switch outsmart advanced kidney cancer?
- Can a new nucleotide analogue boost cancer treatment?
- Can a blast of radiation make immunotherapy work better against kidney cancer?